BMVC|cas:627810-06-4|西域试剂

BMVC,99.92%

产品编号：Bellancom-135775| CAS NO：627810-06-4| 分子式：C₂₈H₂₅I₂N₃| 分子量：657.33

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-135775	￥3000.00	杭州北京（现货）
Bellancom-135775	￥4800.00	杭州北京（现货）
Bellancom-135775	￥9500.00	杭州北京（现货）
Bellancom-135775	￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

BMVC

产品介绍

BMVC 是一种有效的 G-四联体 (G4) 稳定剂和选择性的端粒酶 (telomerase) 抑制剂，IC₅₀ 约为 0.2 μM。BMVC 抑制 Taq DNA 聚合酶，IC₅₀ 约为 2.5 μ M。BMVC 提高了端粒 G4 结构的熔化温度，并加速了端粒长度的缩短。抗癌活性。

生物活性

BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC₅₀ of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC₅₀ of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening. Anticancer activities.

体外研究

BMVC (0.5 μM; 0-18 days; H1299 cells) treatment markedly increases the percentage of sub-G1-phase cells after 18 days.
BMVC (0.5 μM; 0-18 days; H1299 cells) long-term treatment leads to ceasing of cell growth and eventually cell death through apoptosis. The long-term BMVC treatment induces senescence program in H1299 cells.
In BMVC-treated cancer cells, hallmarks of senescence, including morphologic changes, detection of senescence-associated β-galactosidase activity, and decreasesd bromodeoxyuridine incorporation, are detected. The BMVC-induced senescence phenotype is accompanied by progressive telomere shortening and detection of the DNA damage foci, indicating that BMVC caused telomere uncapping after long-term treatments.
BMVC also suppresses the tumor-related properties of cancer cells, including cell migration, colony-forming ability, and anchorage-independent growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis

Cell Line:	H1299 cells
Concentration:	0.5 μM
Incubation Time:	0 day, 6 days, 12 days, 18 days
Result:	The percentage of sub-G1-phase cells was markedly increased after 18 days.

Apoptosis Analysis

Cell Line:	H1299 cells
Concentration:	0.5 μM
Incubation Time:	0 day, 6 days, 12 days, 18 days
Result:	Increased apoptotic cells.

体内研究
(In Vivo)

BMVC (1 mg/kg; intraperitoneal injection; every 3 day; BALB/cAnN.Cg-Foxn1^nu/CrlNarl mice) treatment delays tumorigenic potential of cancer cells in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/cAnN.Cg-Foxn1^nu/CrlNarl mice injected with H1299 cells
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection; every 3 day
Result:	The growth rates of tumors in animals were significantly slower than that of control animals. The tumor cells of the mice were indeed entering apoptosis.

体内研究

BMVC (1 mg/kg; intraperitoneal injection; every 3 day; BALB/cAnN.Cg-Foxn1^nu/CrlNarl mice) treatment delays tumorigenic potential of cancer cells in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/cAnN.Cg-Foxn1^nu/CrlNarl mice injected with H1299 cells
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection; every 3 day
Result:	The growth rates of tumors in animals were significantly slower than that of control animals. The tumor cells of the mice were indeed entering apoptosis.

体内研究

BMVC (1 mg/kg; intraperitoneal injection; every 3 day; BALB/cAnN.Cg-Foxn1^nu/CrlNarl mice) treatment delays tumorigenic potential of cancer cells in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/cAnN.Cg-Foxn1^nu/CrlNarl mice injected with H1299 cells
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection; every 3 day
Result:	The growth rates of tumors in animals were significantly slower than that of control animals. The tumor cells of the mice were indeed entering apoptosis.